July 5, 2016

VALUATION WATCH: Overvalued stocks now make up 36.77% of our stocks assigned a valuation and 12.33% of those equities are calculated to be overvalued by 20% or more. Three sectors are calculated to be overvalued.

If you cannot display this bulletin properly, GO HERE

UPGRADES

--ValuEngine Top-Five BUY/STRONG BUY Upgrades

ValuEngine tracks more than 7000 US equities, ADRs, and foreign stock which trade on US exchanges as well as @1000 Canadian equities.  When EPS estimates are available for a given equity, our model calculates a level of mispricing or valuation percentage for that equity based on earnings estimates and what the stock should be worth if the market were totally rational and efficient--an academic exercise to be sure, but one which allows for useful comparisons between equities, sectors, and industries. Using our Valuation Model, we can currently assign a VE valuation calculation to more than 2800 stocks in our US Universe.

We combine all of the equities with a valuation calculation to track market valuation figures and use them as a metric for making calls about the overall state of the market.  Two factors can lower these figures-- a market pullback, or a significant rise in EPS estimates.

We also use trading data to provide forecast estimates for a variety of time horizons for almost ever equity in our database. Our Buy/Sell/Hold recommendations are based upon the 1-year forecast return figure. Using valuation and forecast figures, you can rank and rate our covered stocks against each other, to find out, in an objective and systematic way, the most attractive investment targets based on your own risk/reward parameters. We re-calculate the entire database every trading day, so you are assured that every proprietary valuation and forecast datapoint is as up-to-date as possible.

So, for today's bulletin we used our website's advanced screening functions to search for UPGRADES to BUY or STRONG BUY with complete forecast and valuation data. They are presented by one-month forecast return. Titan Pharmaceuticals, Inc. (TTNP) is the leader here.

Below is today's data on Titan Pharmaceuticals, Inc. (TTNP):

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

VALUENGINE RECOMMENDATION: ValuEngine updated its recommendation from HOLD to BUY for TITAN PHARMA on 2016-07-01. Based on the information we have gathered and our resulting research, we feel that TITAN PHARMA has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE Momentum and P/E Ratio.

You can download a free copy of detailed report on TTNP from the link below.

ValuEngine Forecast
	Target Price*	Expected Return
1-Month	5.49	0.89%
3-Month	5.52	1.40%
6-Month	5.56	2.14%
1-Year	6.02	10.63%
2-Year	5.52	1.53%
3-Year	5.35	-1.62%

Valuation & Rankings
Valuation	7.70% undervalued	Valuation Rank(?)	53
1-M Forecast Return	0.89%	1-M Forecast Return Rank	96
12-M Return	26.76%	Momentum Rank(?)	88
Sharpe Ratio	-0.15	Sharpe Ratio Rank(?)	45
5-Y Avg Annual Return	-12.09%	5-Y Avg Annual Rtn Rank	35
Volatility	82.04%	Volatility Rank(?)	19
Expected EPS Growth	-58.06%	EPS Growth Rank(?)	5
Market Cap (billions)	0.60	Size Rank	59
Trailing P/E Ratio	17.55	Trailing P/E Rank(?)	66
Forward P/E Ratio	41.85	Forward P/E Ratio Rank	9
PEG Ratio	n/a	PEG Ratio Rank	n/a
Price/Sales	787.37	Price/Sales Rank(?)	1
Market/Book	109.20	Market/Book Rank(?)	2
Beta	1.74	Beta Rank	16
Alpha	0.19	Alpha Rank	85

DOWNLOAD A FREE SAMPLE OF OUR TITAN PHARMACEUTICALS (TTNP) REPORT BY CLICKING HERE

ValuEngine Market Overview

ValuEngine Sector Overview